Patents Assigned to Cardero Therapeutics, Inc.
  • Patent number: 10052316
    Abstract: The present invention relates to compositions and methods for prophylactic and/or therapeutic treatment of conditions related to mitochondrial function. In various aspects, the present invention comprises administering one or more compounds selected from the group consisting of epicatechin, an epicatechin derivative, catechin, a catechin derivative, nicorandil, and a nicorandil derivative in an amount effective to ameliorate mitochondrial toxicity caused by administration of a chemical, food, or drug.
    Type: Grant
    Filed: June 5, 2012
    Date of Patent: August 21, 2018
    Assignee: Cardero Therapeutics, Inc.
    Inventors: Francisco Villarreal, Alan Maisel, George Schreiner, Guillermo M. Ceballos Reyes, Pam Taub
  • Publication number: 20180193306
    Abstract: The present invention relates to compounds and compositions and their applications as pharmaceuticals for treating, preventing, or reversing injury to skeletal or cardiac muscles, for treating or preventing diseases relating to the structure and function of skeletal or cardiac muscle, and for inducing regeneration or restructuring of skeletal or cardiac muscle as a means of treating diseases relating to abnormalities in skeletal or cardiac muscle structure and function in a human or animal subject. Further aspects relate to the same or similar applications for bone and bone diseases.
    Type: Application
    Filed: February 20, 2018
    Publication date: July 12, 2018
    Applicant: Cardero Therapeutics, Inc.
    Inventors: George F. SCHREINER, Guillermo CEBALLOS, Sundeep DUGAR
  • Patent number: 9901564
    Abstract: The present invention relates to compounds and compositions and their application as pharmaceuticals for treating, preventing, or reversing injury to skeletal or cardiac muscles, for treating or preventing diseases relating to the structure and function of skeletal or cardiac muscle, and for inducing regeneration or restructuring of skeletal or cardiac muscle as a means of treating diseases relating to abnormalities in skeletal or cardiac muscle structure and function in a human or animal subject.
    Type: Grant
    Filed: March 22, 2013
    Date of Patent: February 27, 2018
    Assignee: CARDERO THERAPEUTICS, INC.
    Inventors: George F. Schreiner, Guillermo Ceballos, Sundeep Dugar
  • Patent number: 9187448
    Abstract: The present invention relates to compounds, compositions, and methods for treatment of conditions related to mitochondrial function. In various aspects, the present invention comprises administering one or more epicatechin derivatives in an amount effective to stimulate mitochondrial function in cells. The compounds, compositions, and methods described herein provide for reducing infarct size in the heart following permanent ischemia or ischemia/reperfusion event or method for delaying, attenuating or preventing adverse cardiac remodeling, and can assist in prevention of impaired mitochondria biogenesis and thus prevention of the consequences of impaired mitochondrial biogenesis in various diseases and conditions, as well as provide for the active therapy of mitochondrial depletion that may have already occurred.
    Type: Grant
    Filed: August 6, 2012
    Date of Patent: November 17, 2015
    Assignee: CARDERO THERAPEUTICS, INC.
    Inventors: Cyrus K. Becker, George F. Schreiner, Sundeep Dugar, Dinesh Mahajan
  • Publication number: 20140256741
    Abstract: The present invention relates to compounds, compositions, and methods for treatment of conditions related to mitochondrial function. In various aspects, the present invention comprises administering one or more epicatechin derivatives in an amount effective to stimulate mitochondrial function in cells. The compounds, compositions, and methods described herein provide for reducing infarct size in the heart following permanent ischemia or ischemia/reperfusion event or method for delaying, attenuating or preventing adverse cardiac remodeling, and can assist in prevention of impaired mitochondria biogenesis and thus prevention of the consequences of impaired mitochondrial biogenesis in various diseases and conditions, as well as provide for the active therapy of mitochondrial depletion that may have already occurred.
    Type: Application
    Filed: August 6, 2012
    Publication date: September 11, 2014
    Applicant: Cardero Therapeutics, Inc.
    Inventors: Cyrus K. Becker, George F. Schreiner, Sundeep Dugar, Dinesh Mahajan